A majority of patients with psychiatric comorbidities secondary to tuberous sclerosis complex (TSC) respond to psychoactive medications, according to a single-centre analysis of clinical records (Chung et al. Ann Clin Psychiatry 2011; 23: 263-269).
Latest News
Future look: novel AD therapies in phase III testing
January 25, 2012Two novel compounds currently in development – bapineuzumab and solanezumab – for the treatment of Alzheimer’s disease expect to release phase III data in 2012. Those results may usher in a new era, or may add names to the list of high-profile setbacks in AD therapeutics such as tarenflurbil (Myriad), semagacestat (Lilly/Elan), tramiprosate (Neurochem) and AN1792 (Elan).
MCI in PD: Movement Disorder Society Task Force report
January 25, 2012An estimated 26.7% of patients with Parkinson’s disease experience mild cognitive impairment (MCI), according to a Movement Disorder Society task force report (Litvan et al. Mov Disord 2011; 26: 1814-1824). The estimated point prevalence of MCI is 30%; the estimated cumulative prevalence is >75% for PD patients surviving more than 10 years (Hely et al. Mov Disord 2008; 60: 387-392; Bronnick et al. J Neurol Neurosurg Psychiatry 2006; 77: 1136-1142).
Calcium blockers for tardive dyskinesia
January 25, 2012Over the past two decades, a number of small studies and case reports have suggested that calcium channel blockers (e.g. nifedipine, verapamil, diltiazem) may be beneficial in the treatment of neuroleptic-induced tardive dyskinesia (Suddath et al. Pharmacol Biochem Behav 1991; 39: 743-745; Duncan et al. J Clin Psychopharmacol 1990; 10: 414-416).